Seaport Therapeutics Names Lauren White as Chief Financial Officer

Rhea-AI Summary

Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.

Positive

• Key executive from ImmunoGen's successful $10.1B acquisition by AbbVie joins the company
• Experienced CFO with track record in successful commercial drug launch (ELAHERE®)
• Strong background in M&A, strategic partnering, and financial planning

Negative

• None.

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE: ABBV) for $10.1 billion in 2024.

“I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatment of anxiety, depression and other neuropsychiatric disorders,” said Daphne Zohar, Founder and Chief Executive Officer at Seaport. “Her strong leadership background in biotech finance will be valuable as we chart an efficient path to delivering these important new medicines to patients.”

Ms. White brings over 22 years of corporate finance, accounting, strategic partnering and investor relations expertise to Seaport. As the CFO at ImmunoGen, Ms. White played a key role on the internal deal team, conducting thorough analysis and due diligence during the M&A process with multiple potential buyers, which ultimately led to the successful acquisition of the company by AbbVie. Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE^®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before joining ImmunoGen, Ms. White served as Chief Financial Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics (NASDAQ: CCCC), where she was responsible for developing and leading the company's financial, capital, and procurement strategies.

Prior to that, Ms. White held roles of increasing responsibility at Novartis (NYSE: NVS), most recently serving as Global Head of Financial Planning and Analysis for the Novartis Institutes for BioMedical Research (NIBR), where she drove financial strategy and business planning. Before Novartis, Ms. White held strategy and marketing roles with Boston Consulting Group and General Electric. Ms. White received a BS from the Carroll School of Management at Boston College and earned an MBA from Harvard Business School.

“I’m excited to join the outstanding team at Seaport at this important stage of development,” said Ms. White. “I look forward to working with our team and collaborators to leverage our recent financial progress and support Seaport’s mission to deliver meaningful medicines that positively impact the lives of patients and their families.”

About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105739129/en/

Shannon Costello

Seaport Therapeutics

publicrelations@seaporttx.com

Source: Seaport Therapeutics

FAQ

When was ImmunoGen (IMGN) acquired by AbbVie?

ImmunoGen (IMGN) was acquired by AbbVie for $10.1 billion in 2024.

What was Lauren White's role in ImmunoGen (IMGN) before joining Seaport?

Lauren White served as Chief Financial Officer at ImmunoGen (IMGN), where she played a key role in the M&A process with AbbVie and helped maximize the commercial launch of ELAHERE®.

What was the acquisition value of ImmunoGen (IMGN)?

ImmunoGen (IMGN) was acquired by AbbVie for $10.1 billion.